The main benefits of GLP-1 therapy include: Enhanced insulin secretion in response to meals Reduced glucagon release, preventing high blood sugar levels Slowed gastric emptying, leading to prolonged satiety Decreased appetite, which may help with weight loss Currently available GLP-1 receptor agonists include drugs like liraglutide (Victoza), semaglutide (Ozempic, Wegovy), exenatide (Byetta), and dulaglutide (Trulicity)
With Lilly now manufacturing a variety of different strengths of single-dose vials of Zepbound it makes a much harder case for compounders to continue marketing their own versions
Clinical studies show that patients may lose approximately 10% to 20% of body weight over time when these medications are combined with appropriate lifestyle changes
Goldney J, Barker MM, Sargeant JA, Daynes E, Papamargaritis D, Shabnam S, et al
Shaharyar Khan, PhD, Chief Scientific Officer Number Of Employees: ~27 Stage: Private, Series B2 Financial Snapshot: Has raised $224M total across funding rounds, including a $132M Series B Notable Investors: RA Capital Management
